MDWD News and Press, MediWound Ltd. From 03/17/22

MediWound Ltd. (MDWD) Q4 2021 Earnings Conference Call March 17, 2022 08:30 ET Company Participants Monique Kosse - Investor Relations Sharon Malka - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Kevin DeGeeter - Oppenheime...

MediWound press release (NASDAQ:MDWD): Q4 GAAP EPS of -$0.15 in-line. Revenue of $5.49M (-18.1% Y/Y) misses by $0.05M. For further details see: MediWound GAAP EPS of -$0.15 in-line, revenue of $5.49M misses by $0.05M

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conferenc...

ACN,ALDX,AVDL,OTCQX:AYRWF,CMC,CSIQ,DBI,DG,DXLG,OTCQX:EDVMF,GIII,HUT,IMV,KIRK,LICY,LQDA,MDWD,OTCQX:NLCP,OTCPK:PNGAY,RDHL,SIG,SYBX,OTCPK:VEOEY,XNET,ZEPP For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

MediWound (NASDAQ:MDWD) is scheduled to announce Q4 earnings results on Thursday, March 17th, before market open. The consensus EPS Estimate is -$0.15 (-150.0% Y/Y) and the consensus Revenue Estimate is $5.54M (-17.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisio...

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that o...

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the ...

Gainers: DBV Technologies (NASDAQ:DBVT) +16%. EyePoint Pharmaceuticals (NASDAQ:EYPT) +14%. Antares Pharma (NASDAQ:ATRS) +10%. Nuvalent (NASDAQ:NUVL) +8%. Aquestive Therapeutics (NASDAQ:AQST) +7%. Losers: NuCana (NASDAQ:NCNA) -54%. MediWound (NASDAQ:MDWD) -15%.&#x...

MediWound (NASDAQ:MDWD) plunged 17.9% premarket after pricing its underwritten public offering of 5.2M shares at a public offering price of $1.92/share. Gross proceeds are expected to be ~$10M. Underwriters granted 30-day option to purchase up to an additional 78...

YAVNE, Israel, March 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced the pr...